EMEA-000118-PIP02-10-M03
Key facts
| Invented name |
Orencia
|
| Active substance |
Abatacept
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0128/2014
|
| PIP number |
EMEA-000118-PIP02-10-M03
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-000118-PIP02-10-M03
|
| Compliance opinion date |
23/03/2018
|
| Compliance outcome |
positive
|